Patrick Campbell

An analysis from ADA 2021 suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.

Using banked samples from the CANVAS trial, investigators demonstrate the ability of KidneyIntelX to monitor therapeutic response to SGLT2 inhibitors and predict disease progression in patients with type 2 diabetes and chronic kidney disease.

Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.

Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.

A pair of studies presented at ADA 2021 detail the effects of an investigational 2.0 mg dose of semaglutide compared to semaglutide 1.0 mg (Ozempic) on glycemic control and body weight in patients with type 2 diabetes in SUSTAIN FORTE.

Data from a RCT demonstrate the impact of high-frequency spinal cord stimulation on pain and quality of life among patients with a history of painful diabetic neuropathy lasting more than a year.

Research from the T1D Exchange Registry paints a picture describing current trends in the management of diabetes among patients with type 1 diabetes enrolled within the online registry.

An analysis of FIDELIO-DKD demonstrates the benefits of finerenone use was consistent regardless of baseline insulin use among patients with type 2 diabetes and CKD included in the phase 3 trial.

A simulation model assesses the projected impact of the Medicare Part D Senior Savings Model on healthcare spending and outcomes among patients covered by Medicare using insulin.

A look at the medical spending of more than 500 patients with type 2 diabetes who initiated therapy with real-time continuous glucose monitoring details the reductions in medical costs associated with initiation of real-time CGM.

A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population.

A FIDELIO-DKD analysis presented at ADA 2021 suggests the renal and cardiovascular benefits of finerenone were consistent, irrespective of background GLP-1 RA use and indicate the presence of both was associated with even greater reductions in albuminuria.

A study assessing factors associated with achieving recommended levels of HbA1c testing provide insight into the impact of provider type and other factors on the likelihood of having at least 2 HbA1c measurements in a year.

While advances in glucose-lowering therapies have been practice-changing, a new analysis suggests patients could achieve greater cost-effectiveness with older agents.

A prespecified analysis of DAPA-CKD presented at ADA 2021 suggests use of dapagliflozin reduced the incidence of type 2 diabetes by nearly 40% among patients with chronic kidney disease but without diabetes within the phase 3 trial.

While investigators found no differences in outcomes based on diabetes status alone, results indicated those who were not managing their diabetes had more severe outcomes and longer length of hospitalization from COVID-19.

Data from an analysis of FIDELIO-DKD suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the semaglutide 2.4 mg (Wegovy) approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.

A review of available data suggests patients with nephrotic syndrome were at a 19-fold greater risk of end-stage kidney disease and a 3-fold greater risk of acute coronary syndrome events.

Data from HIV POST SCD details the incidence rate of sudden cardiac death among HIV-positive persons compared to the general population.

Data from the REWIND trial suggests men receiving dulaglutide had an 8% lower risk for incident erectile dysfunction than their counterparts who were randomized to placebo therapy.

New research suggests statin use was associated with significant reductions in risk of cancer among heart failure patients, with this apparent risk reduction becoming greater with prolonged use.

An analysis of contemporary trends related to preventive aspirin use suggests older patients with diabetes were twice as likely to use preventive aspirin as their counterparts without diabetes, with many doing so despite it being considered inappropriate based on new guidance.

A look at more than 300 clinical trials examining dietary supplements and alternative therapies for inducing weight loss has returned evidence detailing a lack of high-quality evidence related to the efficacy of these approaches.

An analysis of data from an RCT suggests statin use does not negatively impact the neurocognitive health or memory of older patients.

Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.

Using data from within NHANES from 2011-2018, investigators from Johns Hopkins University provide a comprehensive overview of the use of aspirin for primary and secondary prevention among older patients based on diabetes status.

The FDA has granted approval to dabigatran etexilate (Pradaxa) for treatment of blood clots in pediatric patients with VTE and prevention of recurrent blood clots in those who have completed treatment for VTE.

A meta-analysis of 14 studies suggests use of antihypertensive agents known to cross the blood-brain barrier was associated with improved memory recall over time compared to nonpenetrant agents in older adults with hypertension.

A pilot trial in 29 women suggests a combination of metformin and high dose fish oil could reduce triglycerides and ApoB-remnants among young women with polycystic ovary syndrome.